Publications

484 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

Fingolimod (Gilenya®)

The National Health Care Institute has advised on amending the conditional inclusion of the medicine fingolimod (Gilenya®) in the ...

Report | 08-07-2016
Future scenarios about drug development and drug pricing

This report is the result of a consultative and deliberative process — initiated by the Belgian Healthcare Knowledge Centre (KCE) ...

Report | 28-06-2016
Tranylcypromine (Tracydal®) in patients with a severe multi-resistant depressive disorder

The National Health Care Institute carried out a budget impact analysis for the medicine tranylcypromine (Tracydal®). They ...

Report | 15-06-2016
Tolperison (Tolpermyo®)

The National Health Care Institute has drawn up a pharmacotherapeutic report for the medicine tolperison (Tolpermyo®), whereby it ...

Report | 25-05-2016
Brivaracetam (Briviact®)

The National Health Care Institute has approved a pharmacotherapeutic report for the medicine brivaracetam (Briviact®), whereby ...

Report | 23-05-2016
Lumacaftor/ivacaftor (Orkambi®) by Cystic fibrosis

Based on the GVS criteria, lumacaftor/ivacaftor (Orkambi®) can not be replaced by another drug in the GVS. The assessment ...

Report | 13-05-2016
Eculizumab (Soliris®) for the treatment of patients with paroxysmal nocturnal haemogloninuria

The National Health Care Institute has re-assessed the medicine eculizumab (Soliris®) for the treatment of patients with ...

Report | 13-05-2016
Levo floxacin (Quinsair®) for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa

The National Health Care Institute carried out a marginal assessment of the medicine levofloxacin (Quinsair®), whereby they came ...

Report | 03-05-2016
Early Intensive Neurorehabilitation of adults with unresponsive wakefulness syndrome or a prolonged minimally conscious state

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.

Report | 29-03-2016
Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease

The National Health Care Institute has approved a pharmacotherapeutic report for the medicine safinamide (Xadago®). They reached ...

Report | 21-03-2016

Publications

484 publications

Fingolimod (Gilenya®)

Future scenarios about drug development and drug pricing

Tranylcypromine (Tracydal®) in patients with a severe multi-resistant depressive disorder

Tolperison (Tolpermyo®)

Brivaracetam (Briviact®)

Lumacaftor/ivacaftor (Orkambi®) by Cystic fibrosis

Eculizumab (Soliris®) for the treatment of patients with paroxysmal nocturnal haemogloninuria

Levo floxacin (Quinsair®) for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa

Early Intensive Neurorehabilitation of adults with unresponsive wakefulness syndrome or a prolonged minimally conscious state

Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease

Go to